• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[All-cause mortality and incidence of major cardiovascular events in hypertensive patients with ASCOT-type profile in a Spanish population setting].[西班牙人群中具有ASCOT型特征的高血压患者的全因死亡率和主要心血管事件发生率]
Aten Primaria. 2010 Aug;42(8):420-30. doi: 10.1016/j.aprim.2009.09.027. Epub 2010 Feb 8.
2
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.在 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy 研究中,高血压患者接受降压和降脂治疗后的长期死亡率:一项随机化两因素试验的 16 年随访结果。
Lancet. 2018 Sep 29;392(10153):1127-1137. doi: 10.1016/S0140-6736(18)31776-8. Epub 2018 Aug 26.
3
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.盎格鲁-斯堪的纳维亚心脏结局试验降脂组:试验结束后2年的延长观察
Eur Heart J. 2008 Feb;29(4):499-508. doi: 10.1093/eurheartj/ehm583. Epub 2008 Jan 5.
4
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.盎格鲁-斯堪的纳维亚心脏结局试验中抗高血压治疗及阿托伐他汀的获益:降脂治疗组扩展研究
J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.
5
Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study.冠状动脉血管运动异常但冠状动脉造影正常的患者,2型糖尿病患者的心血管结局比动脉高血压患者更差:一项10年随访研究。
Atherosclerosis. 2005 Nov;183(1):113-20. doi: 10.1016/j.atherosclerosis.2005.02.030. Epub 2005 Apr 15.
6
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.阿托伐他汀在预防糖尿病和/或代谢综合征患者心血管事件中的疗效。
Drugs. 2007;67 Suppl 1:43-54. doi: 10.2165/00003495-200767001-00005.
7
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).阿托伐他汀对2532例2型糖尿病患者心血管事件的影响:盎格鲁-斯堪的纳维亚心脏结局试验——降脂分支(ASCOT-LLA)。
Diabetes Care. 2005 May;28(5):1151-7. doi: 10.2337/diacare.28.5.1151.
8
Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).血浆肾素活性是否可作为预测降压治疗的高血压患者肾脏和心血管结局的生物标志物?来自盎格鲁-斯堪的纳维亚心脏结局试验(ASCOT)的观察。
Eur Heart J. 2012 Dec;33(23):2970-9. doi: 10.1093/eurheartj/ehs241. Epub 2012 Aug 31.
9
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort.代谢综合征及其组分与心血管疾病风险:RIVANA 队列的 13 年前瞻性研究。
Cardiovasc Diabetol. 2020 Nov 22;19(1):195. doi: 10.1186/s12933-020-01166-6.
10
Cardiovascular morbidity and mortality among hypertensive patients in general practice: the evaluation of long-term systematic management.全科医疗中高血压患者的心血管发病率和死亡率:长期系统管理的评估
J Clin Epidemiol. 1997 Jul;50(7):779-86. doi: 10.1016/s0895-4356(97)00066-8.

本文引用的文献

1
[Cardiovascular complications at 1-year of follow-up in patients with atherothrombosis. On behalf of Spain's REACH Registry].[动脉粥样硬化血栓形成患者随访1年时的心血管并发症。代表西班牙REACH注册研究]
Med Clin (Barc). 2009 Apr 18;132(14):537-44. doi: 10.1016/j.medcli.2008.11.033.
2
[Ten-year incidence of fatal and non-fatal myocardial infarction in the elderly population of Madrid].[马德里老年人群中致命性和非致命性心肌梗死的十年发病率]
Rev Esp Cardiol. 2008 Nov;61(11):1140-9.
3
[ESH/ESC 2007 Guidelines for the management of arterial hypertension].[欧洲高血压学会/欧洲心脏病学会2007年动脉高血压管理指南]
Rev Esp Cardiol. 2007 Sep;60(9):968.e1-94. doi: 10.1157/13109650.
4
[Incidence and prevalence of ischaemic heart disease and cerebrovascular disease in Spain: a systematic review of the literature].[西班牙缺血性心脏病和脑血管疾病的发病率及患病率:文献系统综述]
Rev Esp Salud Publica. 2006 Jan-Feb;80(1):5-15. doi: 10.1590/s1135-57272006000100002.
5
Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study.55岁及以上男性和女性中已确诊和未确诊心肌梗死的发病率:鹿特丹研究
Eur Heart J. 2006 Mar;27(6):729-36. doi: 10.1093/eurheartj/ehi707. Epub 2006 Feb 14.
6
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.盎格鲁-斯堪的纳维亚心脏结局试验-降压分支(ASCOT-BPLA):氨氯地平降压方案按需加用培哚普利与阿替洛尔按需加用苄氟噻嗪预防心血管事件的多中心随机对照试验
Lancet. 2005;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1.
7
[Control of cardiovascular risk factors in primary healthcare: do we control the factors or the risk?].[基层医疗中心血管危险因素的控制:我们控制的是因素还是风险?]
Med Clin (Barc). 2005 Mar 26;124(11):415-6. doi: 10.1157/13072843.
8
Dietary influences on blood pressure: the effect of the Mediterranean diet on the prevalence of hypertension.饮食对血压的影响:地中海饮食对高血压患病率的作用
J Clin Hypertens (Greenwich). 2005 Mar;7(3):165-70; quiz 171-2. doi: 10.1111/j.1524-6175.2005.04079.x.
9
Increasing trends of acute myocardial infarction in Spain: the MONICA-Catalonia Study.西班牙急性心肌梗死发病率上升趋势:莫妮卡-加泰罗尼亚研究
Eur Heart J. 2005 Mar;26(5):505-15. doi: 10.1093/eurheartj/ehi068. Epub 2004 Dec 15.
10
[Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study].[适用于西班牙人群的冠心病风险评估表:多里卡研究]
Med Clin (Barc). 2004 Nov 20;123(18):686-91. doi: 10.1016/s0025-7753(04)75331-2.

[西班牙人群中具有ASCOT型特征的高血压患者的全因死亡率和主要心血管事件发生率]

[All-cause mortality and incidence of major cardiovascular events in hypertensive patients with ASCOT-type profile in a Spanish population setting].

作者信息

Sicras-Mainar Antoni, Fernández de Bobadilla Jaime, Navarro-Artieda Ruth, Rejas-Gutiérrez Javier

机构信息

Dirección de Planificación, Badalona Serveis Assistencials SA, Badalona, Barcelona, España.

出版信息

Aten Primaria. 2010 Aug;42(8):420-30. doi: 10.1016/j.aprim.2009.09.027. Epub 2010 Feb 8.

DOI:10.1016/j.aprim.2009.09.027
PMID:20116891
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7024499/
Abstract

OBJECTIVES

Mediterranean populations are traditionally considered to be associated with lower incidence of cardiovascular events (CVE). However, this might not be homogeneous throughout different patient strata. The goal was to compare the incidence of CVE and all-causes mortality in hypertensive patients with an ASCOT-type profile with that of the rest hypertensive subjects.

METHODS

A retrospective analysis was carried out using a claim database. Hypertensive patients without known cardiovascular disease on antihypertensive therapy included during year 2006 were followed up for two consecutive years to ascertain the incidence of all-causes mortality and any CVE. CVE included any of the following: coronary heart disease, acute myocardial infarction (AMI), angina, stroke, transient ischemic attack (TIA) and peripheral artery disease. Patients with ASCOT and ASCOT-LLA type profiles were identified and compared with non-ASCOT-type profile hypertensive subjects.

RESULTS

A total of 11,104 were included in the analysis; 68.0+/-11.4 years, 41.6% males. More than 73% of subjects fulfilled criteria for ASCOT-type profile. All-causes mortality were numerically higher in ASCOT and ASCOT-LLA subjects compared with non-ASCOT-type; hazard ratio (95% CI)=1.3 (0.8-1.9) and 1.6 (0.9-2.8), respectively. However, any-coronary event rate was significantly higher in ASCOT-type [2.3 (1.8-2.8), p<0.001], as well as in ASCOT-LLA subjects [1.8 (1.3-2.4), p<0.001].

CONCLUSIONS

Hypertensive patients on treatment with ASCOT-type profile are more likely to have any cardiovascular event than those hypertensive patients without ASCOT profile in a Mediterranean setting in Spain.

摘要

目的

传统上认为地中海地区人群心血管事件(CVE)的发病率较低。然而,在不同患者群体中情况可能并非如此。本研究旨在比较具有ASCOT型特征的高血压患者与其他高血压患者的CVE发病率及全因死亡率。

方法

使用索赔数据库进行回顾性分析。对2006年接受抗高血压治疗且无已知心血管疾病的高血压患者进行连续两年的随访,以确定全因死亡率和任何CVE的发生率。CVE包括以下任何一种:冠心病、急性心肌梗死(AMI)、心绞痛、中风、短暂性脑缺血发作(TIA)和外周动脉疾病。识别出具有ASCOT和ASCOT-LLA型特征的患者,并与非ASCOT型特征的高血压患者进行比较。

结果

共有11104例患者纳入分析;年龄68.0±11.4岁,男性占41.6%。超过73%的受试者符合ASCOT型特征标准。ASCOT和ASCOT-LLA受试者的全因死亡率在数值上高于非ASCOT型受试者;风险比(95%CI)分别为1.3(0.8 - 1.9)和1.6(0.9 - 2.8)。然而,ASCOT型患者的任何冠心病事件发生率显著更高[2.3(1.8 - 2.8),p<0.001],ASCOT-LLA受试者也是如此[1.8(1.3 - 2.4),p<0.001]。

结论

在西班牙地中海地区,接受ASCOT型治疗的高血压患者比无ASCOT特征的高血压患者更易发生任何心血管事件。